RRx-001: Phase I data

The open-label, U.S. Phase I DINAMIC trial in 25 patients with resistant solid tumors ages >18 showed that 10, 16.7, 24.6, 33, 55 and 86 mg/m 2 IV RRx-001 once or twice weekly led to no treatment-rela...